61-Year-Old Female Patient

**Tumor Type:** Adenocarcinoma

**Tumor Stage:** Stage III A/B (N1-3)

**Histologic Grade:** Intermediate (2)

**Lymph Node Status:** Positive

**Number of Lymph Nodes Assessed:** 54

**Mismatch Repair (MMR) Status:** N/A

**Lymphovascular Invasion:** Absent

**Perforation:** Absent

**Obstruction:** Absent

**Other Information:** Patient has hypertension

**Treatment:** Capecitabine (Xeloda)
Colon Case Study

CLINICAL EXPERIENCE

Recurrence Score = 13

Prognosis for Stage III A/B Colon Cancer Patients Following Adjuvant Chemotherapy

The clinical validation study included patients from the NSAPB C-07 trial which randomized 409 stage III A/B patients to 5FU/LV versus 5FU/LV+oxaliplatin.¹

The average 5 year risk of recurrence for patients who had a Recurrence Score® result of 13 was:

Other Considerations: The recurrence risk for patients with ≥ 12 nodes examined was lower than the risk for those with < 12 nodes examined.

References: